Binod Dhakal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4491788/publications.pdf

Version: 2024-02-01

122	1,688	361413	361022
papers	citations	20	35
		h-index	g-index

167	167	167	2546
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. British Journal of Haematology, 2022, 197, 28-40.	2.5	9
2	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 83.e1-83.e9.	1.2	9
3	Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. Molecular Cancer Therapeutics, 2022, 21, 502-510.	4.1	3
4	Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e495-e497.	0.4	2
5	Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. Frontiers in Oncology, 2022, 12, 786451.	2.8	8
6	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 2901-2912.	1.6	124
7	Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer Journal, 2022, 12, 34.	6.2	22
8	Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR TÂcell, and BiTE recipients. Cancer Cell, 2022, 40, 340-342.	16.8	35
9	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, 284-293.	1.2	11
10	Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Advances, 2022, 6, 2466-2470.	5.2	29
11	Rap1A, Rap1B, and Î²-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.. Yale Journal of Biology and Medicine, 2022, 95, 45-56.	0.2	0
12	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multiâ€institutional experience. American Journal of Hematology, 2022, 97, .	4.1	4
13	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 2022, 6, 3991-3995.	5.2	5
14	Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer Journal, 2022, 12, .	6.2	3
15	Impact of autologous hematopoietic cell transplantation on disease burden quantified by nextâ€generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology, 2022, 97, 1170-1177.	4.1	3
16	Kinetics of humoral immunodeficiency with bispecific antibody therapy in multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8049-8049.	1.6	0
17	Autonomic nervous system control of multiple myeloma. Blood Reviews, 2021, 46, 100741.	5.7	11
18	Salvage second transplantation in relapsed multiple myeloma. Leukemia, 2021, 35, 1214-1217.	7.2	17

#	Article	IF	Citations
19	Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 225-231.	2.4	17
20	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. Bone Marrow Transplantation, 2021, 56, 9-19.	2.4	22
21	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	4.1	15
22	Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 229-233.	1.3	0
23	Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.. Journal of Clinical Oncology, 2021, 39, 8029-8029.	1.6	1
24	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem, 2021, 2, 375-384.	1.0	2
25	Laboratory Mice â€“ A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Frontiers in Immunology, 2021, 12, 667054.	4.8	2
26	Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e775-e781.	0.4	0
27	Immunotherapy in Multiple Myelomaâ€”Time for a Second Major Paradigm Shift. JCO Oncology Practice, 2021, 17, 405-413.	2.9	10
28	A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. Cells, 2021, 10, 1961.	4.1	16
29	Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood, 2021, 138, 1278-1281.	1.4	101
30	Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. Leukemia Research, 2021, 109, 106648.	0.8	0
31	Metabolically Reprogrammed Polyclonal Autologous Rapa-201 Cell Therapy Yields a Promising Safety and Efficacy Profile in Relapsed and Refractory Multiple Myeloma (RRMM). Blood, 2021, 138, 2838-2838.	1.4	7
32	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial. Blood, 2021, 138, 481-481.	1.4	5
33	Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. Blood, 2021, 138, 4091-4091.	1.4	0
34	Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5). Blood, 2021, 138, 1835-1835.	1.4	10
35	Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy. Blood, 2021, 138, 483-483.	1.4	2
36	Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma. Blood, 2021, 138, 1626-1626.	1.4	3

#	Article	IF	Citations
37	The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Reviews, 2020, 41, 100643.	5.7	26
38	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 2229-2236.	2.0	4
39	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. British Journal of Haematology, 2020, 191, 442-452.	2.5	8
40	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 2011-2017.	2.0	11
41	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1876-1885.	2.0	4
42	Multiple myeloma and COVID-19. Leukemia, 2020, 34, 1961-1963.	7.2	29
43	Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology, 2020, 11, 1285-1292.	1.0	14
44	Trends in the use of therapeutic plasma exchange in multiple myeloma. Journal of Clinical Apheresis, 2020, 35, 307-315.	1.3	4
45	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network metaâ€analysis of phase 3 randomized controlled trials. Cancer, 2020, 126, 2791-2801.	4.1	6
46	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biology of Blood and Marrow Transplantation, 2020, 26, 1288-1297.	2.0	10
47	Use of IV Immunoglobulin G in Heparin-Induced Thrombocytopenia Patients Is Not Associated With Increased Rates of Thrombosis. Chest, 2020, 158, 1172-1175.	0.8	11
48	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biology of Blood and Marrow Transplantation, 2020, 26, 893-901.	2.0	13
49	Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e468-e473.	0.4	4
50	Impact of Autologous Hematopoetic Stem Cell Transplant (AHCT) on Measurable Residual Disease (MRD) By Next Generation Sequencing (NGS) in the Setting of Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Quadruplet Induction.. Biology of Blood and Marrow Transplantation, 2020, 26, S24.	2.0	2
51	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	7.2	27
52	Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data. Blood, 2020, 136, 35-36.	1.4	14
53	The significance of beta-II microglobulin (Î²2M) and International Staging System (ISS) in multiple myeloma (MM) patients (pts.) with renal impairment (RI).. Journal of Clinical Oncology, 2020, 38, 8544-8544.	1.6	1
54	Exploring multiple myeloma survivor interest in lifestyle interventions.. Journal of Clinical Oncology, 2020, 38, e20558-e20558.	1.6	0

#	Article	IF	Citations
55	Budesonide Prophylaxis Reduces Engraftment Syndrome (ES) after Autologous Hematopoietic Cell Transplantation (autoHCT) in Multiple Myeloma (MM). Blood, 2020, 136, 35-36.	1.4	0
56	Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 10-14.	0.9	23
57	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 210-215.	3.0	2
58	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 56.	6.2	15
59	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Network Open, 2019, 2, e196476.	5.9	12
60	An updated single center experience with plerixafor and granulocyte colonyâ€stimulating factor for stem cell mobilization in light chain amyloidosis. Journal of Clinical Apheresis, 2019, 34, 686-691.	1.3	3
61	When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e251-e258.	0.4	4
62	Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leukemia and Lymphoma, 2019, 60, 2558-2562.	1.3	13
63	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 1492-1497.	2.0	23
64	Myeloma sleeper agent in myeloid disguise. Blood, 2019, 134, 3-4.	1.4	6
65	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biology of Blood and Marrow Transplantation, 2019, 25, 827-833.	2.0	23
66	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 683-688.	2.0	18
67	Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. Biology of Blood and Marrow Transplantation, 2019, 25, 921-931.	2.0	21
68	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2019, 134, 860-860.	1.4	80
69	Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM). Blood, 2019, 134, 783-783.	1.4	2
70	Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).. Journal of Clinical Oncology, 2019, 37, 8030-8030.	1.6	2
71	Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood, 2019, 134, 2188-2188.	1.4	0
72	Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation. Blood, 2019, 134, 266-266.	1.4	1

#	Article	IF	Citations
73	Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT). Blood, 2019, 134, 3088-3088.	1.4	0
74	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplantation, 2018, 53, 1210-1213.	2.4	7
75	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. JAMA Oncology, 2018, 4, 343.	7.1	130
76	Peripheral Blood Grafts for T Cellâ€"Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 1664-1670.	2.0	36
77	Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematology,the, 2018, 5, e220-e231.	4.6	76
78	Incidence and survival of therapy related myeloid neoplasm in United States. Leukemia Research, 2018, 71, 95-99.	0.8	24
79	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer, 2018, 18, 593.	2.6	28
80	Pharmacokinetics of High-Dose Propylene Glycolâ€"Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1610-1614.	2.0	8
81	Developing a Case-Based Blended Learning Ecosystem to Optimize Precision Medicine: Reducing Overdiagnosis and Overtreatment. Healthcare (Switzerland), 2018, 6, 78.	2.0	3
82	Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myelomaâ€"Reply. JAMA Oncology, 2018, 4, 1618.	7.1	3
83	Novel biomarkers in multiple myeloma. Translational Research, 2018, 201, 49-59.	5.0	31
84	Risk, Outcomes, and Predictors of Clostridium difficile Infection in Lymphoma: A Nationwide Study. Southern Medical Journal, 2018, 111, 628-633.	0.7	12
85	Trends in utilization and in-hospital outcomes of high dose therapy and autologous stem cell transplantation among patients with AL amyloidosis in the United States.. Journal of Clinical Oncology, 2018, 36, e20000-e20000.	1.6	0
86	Evaluation and identification of protocols for safe and efficacious institutional administration of intravenous immune globulin in hypogammaglobulinemia associated with chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 250-250.	1.6	0
87	Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	0
88	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. Blood, 2018, 132, 3544-3544.	1.4	0
89	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. Blood, 2018, 132, 617-617.	1.4	0
90	Use of Intravenous Immunoglobulin G in HIT: Impact on Thrombosis and Mortality in a Population-Based Study. Blood, 2018, 132, 2512-2512.	1.4	0

#	Article	IF	Citations
91	Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2018, 132, 1998-1998.	1.4	0
92	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 165-172.	0.4	17
93	IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. Chest, 2017, 152, 478-485.	0.8	113
94	Marizomib for central nervous systemâ€multiple myeloma. British Journal of Haematology, 2017, 177, 221-225.	2.5	49
95	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 305-311.e2.	0.4	6
96	A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies. Chest, 2017, 152, e77-e80.	0.8	20
97	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemporary Clinical Trials Communications, 2017, 8, 33-38.	1.1	17
98	Early mortality in patients with acute myelogenous leukemia treated in teaching versus nonâ€teaching hospitals: A large database analysis. American Journal of Hematology, 2017, 92, E563-E565.	4.1	4
99	Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials.. Journal of Clinical Oncology, 2017, 35, 8022-8022.	1.6	0
100	Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.. Journal of Clinical Oncology, 2017, 35, 8012-8012.	1.6	0
101	Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. Case Reports in Hematology, 2016, 2016, 1-4.	0.4	17
102	Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 210-221.	3.8	8
103	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 379-386.	0.4	17
104	Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1773-1780.	2.0	7
105	Marizomib for CNS-Multiple Myeloma. Blood, 2016, 128, 2118-2118.	1.4	6
106	Intravenous Immunoglobulin (IVIg) Is a Highly Effective Treatment for HIT: Critical Role of the IgG Fc Domain in Inhibiting HIT Antibody-Mediated Platelet Activation. Blood, 2016, 128, 2600-2600.	1.4	1
107	Early Mortality in Patients with Acute Promyelocytic Leukemia (APL) Treated in Teaching Versus Non-Teaching Hospitals. Blood, 2016, 128, 2784-2784.	1.4	2
108	Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age. Blood, 2016, 128, 3456-3456.	1.4	1

#	Article	IF	Citations
109	Incidence and Overall Survival of Therapy Related Myeloid Neoplasm in United States. Blood, 2016, 128, 3992-3992.	1.4	1
110	Recent advances in understanding multiple myeloma. F1000Research, 2016, 5, 2053.	1.6	13
111	"Tailoring" Hematopoietic Progenitor Cell Collection: Impact of a Data-Driven Prediction Algorithm for Blood Volume Processing in Large Volume Leukapheresis. Blood, 2016, 128, 2188-2188.	1.4	0
112	Use of "Big Data" to Define Disease Burden, Complication Rates and Healthcare Costs in Patients with Heparin Induced Thrombocytopenia (HIT). Blood, 2016, 128, 418-418.	1.4	0
113	A Novel PF4-Dependent P-Selectin Expression Assay (PEA) Facilitates Early Detection of Pathogenic HIT Antibodies: Implications for Diagnosis and Treatment of HIT. Blood, 2016, 128, 2599-2599.	1.4	11
114	Pilot Study of Prognostic Impact of Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Plasma Levels of CXC-Chemokines (CXCL-4 and CXCL-7) in Patients with Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 4678-4678.	1.4	0
115	Localized Lymph Node Light Chain Amyloidosis. Case Reports in Hematology, 2015, 2015, 1-4.	0.4	3
116	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. Blood, 2015, 126, 2711-2711.	1.4	0
117	Plerixafor and Abbreviated-Course Granulocyte Colonyâ€“Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2014, 20, 1926-1931.	2.0	23
118	eICU STUDY. International Journal of User-Driven Healthcare, 2014, 4, 1-5.	0.1	1
119	Plerixafor plus G-CSF (P+G) compared with G-CSF alone (G) for hematopoietic progenitor cell (HPC) mobilization in AL amyloidosis (AL).. Journal of Clinical Oncology, 2014, 32, 8606-8606.	1.6	0
120	Morbidities of lung cancer surgery in obese patients. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 379-384.	0.8	28
121	How safe is surgery in obese lung cancer patients?. Journal of Clinical Oncology, 2012, 30, e17555-e17555.	1.6	0
122	Pemetrexed Induced Pneumonitis. Clinics and Practice, 2011, 1, e106.	1.4	8